Synthesis and antibacterial activity of 1-N-(1,3-dihydroxy-2-propyl)kanamycin B (UK-31,214).

Richardson, K.; Brammer, K. W.; Jevons, S.; Plews, Rhona M.; Wright, J. R.

doi:10.7164/antibiotics.32.973

Cited by 14 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, both AHBA-like alkane and C1-NH 2 dihydroxypropyl kanamycin analogs showed near equal efficacy despite being structurally dissimilar [90,91].…”

Section: Structure-activity Relationship Of Rings I and Ii Of Both Sumentioning

confidence: 99%

Therapeutic Agents Acting on RNA Targets

Rife

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

There are many therapeutics that target RNA, such as streptomycin, gentamicin, and tetracycline; some of them have been in existence for many years. All of them bind to ribosomal RNA and alter normal ribosome function. The modern strategies of drug discovery and design pertain nearly exclusively to protein targets. However, the field of drug discovery for RNA targets is maturing rapidly, largely due to the exciting ribosome/drug complexes that have recently been solved. Potential RNA drug targets abound for bacterial, viral, and cellular systems. Nevertheless, questions remain as to whether or not compounds can be found that simultaneously satisfy RNA binding and pharmacological properties, such as absorption and membrane permeation. The range of interactions observed, from Coulombic to hydrophobic, and the predicted “drug‐like” qualities of several ribosome binding antibiotics, suggest that the discovery of drugs that target RNA can be a general phenomenon.

show abstract

“…For example, both AHBA-like alkane and C1-NH 2 dihydroxypropyl kanamycin analogs showed near equal efficacy despite being structurally dissimilar [90,91].…”

Section: Structure-activity Relationship Of Rings I and Ii Of Both Sumentioning

confidence: 99%

Therapeutic Agents Acting on RNA Targets

Rife

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

show abstract

Aminoglycosides

Mcgregor

2000

Kirk-Othmer Encyclopedia of Chemical Technology

View full text Add to dashboard Cite

Aminoglycosides are members of the class of antibacterial antibiotics, the structures of which are derived from D ‐streptamine, D ‐2‐deoxystreptamine, or closely related compounds. The term aminocyclitol is sometimes used to identify this group of compounds. In 1991, the most widely used aminoglycosides in medical practice were gentamicin, tobramycin, amikacin, and netilmicin. In general, the aminoglycosides are useful for the treatment of serious infections involving aerobic or facultative gram‐negative bacilli. The most common resistance mechanism involves the inactivation of the aminoglycoside by reactions catalyzed by plasmid‐borne enzymes. Less common resistance mechanisms include decreased affinity for the antibiotic by the bacterial ribosome and decreased rate of transport into the bacterial cytoplasm. The aminoglycosides are administered primarily by intravenous infusion or intramuscular injection. Most of the administered dose is eliminated unmetabolized in the urine. Potential toxicity is a primary limiting factor in the clinical use of aminoglycosides. The most important toxicities are nephrotoxicity, ototoxicity, and to a lesser extent, neuromuscular blockade. All the aminoglycosides in medical practice are capable of causing these adverse events. The effect of this potential is to prevent the use of significantly increased doses to cover difficult infections. The bactericidal mechanisms employed by aminoglycosides are incompletely understood. In the cytoplasm, ribosomal binding leads to misreading of the genetic code and production of abnormal proteins and protein synthesis inhibition. The cause of cell death is uncertain. A large amount of research has been conducted aimed at reducing the limitations in the areas of toxicity and susceptibility to bacterial resistance mechanisms while maintaining the advantages by modification of the aminoglycoside molecular structure. Overall, structural modification has been successful in reducing susceptibility to bacterial inactivation. It has not been possible, however, to substantially dissociate the toxicity potential from the antibacterial activity.

show abstract

Therapeutic Agents Acting on RNA Targets

Rife¹

2003

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

There are many therapeutics that target RNA, such as streptomycin, gentamicin, tetracycline; some of them have been around for years. All of them bind to ribosomal RNA and alter normal ribosome function. The modern strategies of drug discovery and design pertain nearly exclusively to protein targets. However, the field of drug discovery for RNA targets is maturing rapidly, largely because of the exciting ribosome/drug complexes that have recently been solved. Potential RNA drug targets abound for bacteria, viral, and cellular systems. Nevertheless, questions remain as to whether or not compounds can be found that simultaneously satisfy RNA binding and pharmacological properties, such as absorption and membrane permeation. The range of interactions observed, from Coulombic to hydrophobic, and the predicted “drug‐like” qualities of several ribosome binding antibiotics suggest that the discovery of drugs that target RNA can be a general phenomenon.

show abstract

Synthesis and antibacterial activity of 1-N-(1,3-dihydroxy-2-propyl)kanamycin B (UK-31,214).

Cited by 14 publications

References 2 publications

Therapeutic Agents Acting on RNA Targets

Therapeutic Agents Acting on RNA Targets

Aminoglycosides

Therapeutic Agents Acting on RNA Targets

Contact Info

Product

Resources

About